Cindy Lipsanen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE Preclinical data showed enhancement of breast cancer cell death when G3139 was combined with anthracyclines and taxanes. We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC). EXPERIMENTAL DESIGN Following a(More)
  • 1